ClinicalTrials.gg
TerminatedNCT03848832ARCHUpdated Sep 2, 2022Results posted

Efficacy and Safety of Cannabidiol Oral Solution (GWP42003-P, CBD-OS) in Patients With Rett Syndrome

A Phase 3 interventional study of GWP42003-P and Placebo in Rett Syndrome and RTT, sponsored by Jazz Pharmaceuticals. Terminated at 26 sites in 4 countries. Open to participants aged 2 Years to 18 Years. Per ClinicalTrials.gov, last updated 2022-09-02.

Sponsored by Jazz Pharmaceuticals · Phase 3, Interventional, and Treatment

Why this study was terminated
The study was terminated due to enrollment challenges and the COVID-19 pandemic.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
29
Allocation
Randomized
Ages
2 Years to 18 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 55 studies in Rett Syndrome with a site in United States — 11 open to participants now, 21 under way, 5 of them phase 3. Rett Syndrome · United States.

Enrollment
20th of 34
29 · median 32
Started
2019
with 3 others
Phase 3
11 of 55
2 open now
Registered
27th of 55
by date
Lead sponsor
2 of 55
Jazz Pharmaceuticals

Among the 55 studies in Rett Syndrome with a site in United States, this one is the 20th largest by enrollment of the 34 interventional ones that give a count, is one of 4 that started in 2019, is one of 11 in phase 3, and was the 27th registered.

Rett Syndrome

96 studies on the registry are indexed under Rett Syndrome; 19 are open to participants now.

Browse Rett Syndrome studies →

Open to participants now

11 of the 55 studies in Rett Syndrome with a site in United States are open now. Recruiting first, the newest first:

6 more — sign in →

All 11 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 14 Rett Syndrome studies recruiting now, 4 (29%) set no upper age limit and 7 (50%) stop at 75 or younger; 12 take children under 18; 3 take healthy volunteers.

This study: 2 Years to 18 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 55 studies in Rett Syndrome with a site in United States, or all of them as a file.
02

Study summary

To evaluate the efficacy of cannabidiol oral solution (GWP42003-P, CBD-OS) in reducing symptom severity when compared with placebo, in participants with Rett syndrome.

03

Conditions studied

  • Rett Syndrome
  • RTT

Browse trials for

Keywords

  • Cannabidiol
  • CBD
  • Epidiolex
  • GWP42003-P
04

Who can participate

Ages eligible
2 Years to 18 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Participant (if possessing adequate understanding, in the investigator's opinion) and/or their parent(s)/legal representative is willing and able to give /assent for participation in the trial.
  • Participant and their caregiver are willing and able (in the investigator's opinion) to comply with all trial requirements (including the completion of all caregiver assessments by the same caregiver throughout the trial).
  • Participant must weigh at least 10 kilograms.
  • Clinical diagnosis of Rett syndrome (typical or atypical), defined according to RettSearch Consortium criteria
  • Confirmed pathogenic genetic mutation of the MECP2 gene
  • Participant must be post-regression (≥ 6 months since last loss of hand use or verbal language or gross motor regression).
  • Participant must have a disease severity of between 10 and 36, defined according to the Clinical Severity Scale (CSS).
  • All medications or interventions (including antiepileptic drugs [AEDs] and non-pharmacological interventions - dietary supplements, probiotics, physical therapy, speech therapy, etc.) for Rett syndrome-related symptoms must have been stable for 4 weeks prior to screening and the participant/caregiver must be willing to maintain a stable regimen throughout the trial.
  • Ability to swallow the medicinal product (IMP) provided as a liquid solution, or the ability for IMP to be delivered via gastrostomy (G) or nasogastric (NG) feeding tube (only G-or NG-tubes made from polyurethane or silicon are allowed)
  • Participant and/or parent(s)/legal representative is willing to allow the responsible authorities to be notified of participation in the trial, if mandated by local law.
  • Participant and/or parent(s)/legal representative is willing to allow the participant's primary care practitioner (if they have one) and consultant (if they have one) to be notified of participation in the trial, if the primary care practitioner/consultant is different than the investigator.

Key Exclusion Criteria:

  • Participant meets exclusion criteria for Rett syndrome diagnosis (traumatic brain injury, neurometabolic disease, or severe infection that causes neurological problems; grossly abnormal psychomotor development in the first 6 months of life).
  • Participant has abnormal laboratory values, in the investigator's opinion.
  • Participant is taking more than 2 concurrent AEDs.
  • Any history of suicidal behavior or any suicidal ideation in the last month or at screening
  • Clinically relevant abnormalities in the (ECG) measured at screening or randomization
  • Concurrent cardiovascular conditions which will, in the investigator's opinion, interfere with the ability to assess their ECGs or put the participant at risk because of participation in the trial
  • First or second degree relative with a history of significant ECG abnormalities, in the opinion of the investigator (e.g. premature cardiac arrest, sudden death)
  • Any known or suspected to cannabinoids or any of the of the IMP (active or placebo), such as sesame oil
  • Participant has moderately impaired hepatic function at screening, defined as (ALT) or aspartate aminotransferase (AST) > 3 × (ULN) or total > 2 × ULN.
  • Participant is of , unless willing to ensure that they or their partner use a highly effective method of (e.g., combined [estrogen and progestogen containing] hormonal contraception associated with inhibition of ovulation [oral, intravaginal, or transdermal], progestogen-only hormonal contraception associated with inhibition of ovulation [oral, injectable, or implantable], intrauterine devices/hormone-releasing systems, bilateral tubal occlusion, vasectomized partner, sexual abstinence) during the trial and for 3 months thereafter.
  • Pregnant (positive pregnancy test) or lactating
  • Received an IMP within the 3 months prior to screening
  • Participant has been taking felbamate for less than 1 year prior to screening.
  • Currently using or has used recreational or medicinal cannabis, cannabinoid-based medications (including Sativex®), or cannabidiol oral solutions (including CBD-OS [GWP42003-P]) within the 3 months prior to screening and is unwilling to abstain for the duration of the trial
  • Participant has a positive delta-9-tetrahydrocannabinol (THC) test at screening.
  • Any other systemic dysfunction (e.g., gastrointestinal, renal, respiratory) or significant disease or disorder which, in the opinion of the investigator, may either put the participant at risk because of participation in the trial, may influence the result of the trial, or the participant's ability to participate in the trial
  • Any abnormalities identified following a physical examination of the participant that, in the opinion of the investigator, would jeopardize the safety of the participant if she took part in the trial
  • Participant has been previously randomized into this trial.
  • Participant has traveled outside the country of residence planned during the trial.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
29 participants (actual)

Study arms

  • Experimental
    5 milligrams per kilogram per day (mg/kg/day) GWP42003-P

    100 milligrams per milliliter (mg/mL) GWP42003-P oral solution. Taken twice daily (morning and evening).

    Drug: GWP42003-P

  • Experimental
    15 mg/kg/day GWP42003-P

    100 mg/mL GWP42003-P oral solution. Taken twice daily (morning and evening).

    Drug: GWP42003-P

  • Placebo comparator
    Placebo

    Placebo oral solution (0 mg/mL GWP42003-P) volume matched to 5 mg/kg/day or 15 mg/kg/day GWP42003-P. Taken twice daily (morning and evening).

    Drug: Placebo

Interventions

  • GWP42003-P presented as an oral solution containing cannabidiol

    Also known as: Cannabidiol, CBD, Epidiolex, CBD-OS

  • DrugPlacebo

    Matching placebo oral solution

06

What researchers measure

Primary outcomes

  1. Change From Baseline in the Mean Rett Syndrome Behaviour Questionnaire (RSBQ) Total Score at Week 24 for the 15 mg/kg/Day GWP42003-P Dose Level Compared With Placebo

    RSBQ is a caregiver-completed questionnaire that measures the frequency of current disease characteristics (45 items) in individuals with Rett Syndrome. Each item is rated on a 3-point scale (0-2); 0 indicating an item that is "not true as far as you know," 1 indicating an item is "somewhat or sometimes true," and 2 indicating an item that is "very true or often true." Item 31 ("Uses eye gaze to convey feelings, needs and wishes") is reverse scored (0 indicating "very true or often true", 1 indicating "somewhat or sometimes true," and 2 indicating "not true as far as you know"). The total summed score ranges from 0 to 90, with higher scores representing greater severity.

    Time frame: Baseline; Week 24

Secondary outcomes

  1. Change From Baseline in the Mean RSBQ Total Score at Week 24 for the 5 mg/kg/Day GWP42003-P Dose Level Compared With Placebo

    RSBQ is a caregiver-completed questionnaire that measures the frequency of current disease characteristics (45 items) in individuals with Rett Syndrome. Each item is rated on a 3-point scale (0-2); 0 indicating an item that is "not true as far as you know," 1 indicating an item is "somewhat or sometimes true," and 2 indicating an item that is "very true or often true." Item 31 ("Uses eye gaze to convey feelings, needs and wishes") is reverse scored (0 indicating "very true or often true", 1 indicating "somewhat or sometimes true," and 2 indicating "not true as far as you know"). The total summed score ranges from 0 to 90, with higher scores represent greater severity.

    Time frame: Baseline; Week 24

  2. Mean Clinical Global Impressions - Improvement (CGI-I) Score at Week 24

    CGI-I is a 7-point scale that requires the clinician to assess how much a participant's illness has improved or worsened relative to a Baseline state at the beginning of the intervention. This is rated as: 1 = very much improved; 2 = much improved; 3 = minimally improved; 4 = no change; 5 = minimally worse; 6 = much worse; or 7 = very much worse.

    Time frame: Baseline; Week 24

  3. Change From Baseline in Mean Clinician Global Impressions - Severity (CGI-S) Score at Week 24

    CGI-S is a 7-point scale that requires the clinician to rate the severity of the participant's illness at the time of assessment relative to the clinician's experience with participants who had the same diagnosis. This is rated as: 1 = normal, not at all ill; 2 = borderline ill; 3 = mildly ill; 4 = moderately ill; 5 = markedly ill; 6 = severely ill; or 7 = extremely ill.

    Time frame: Baseline; Week 24

  4. Change From Baseline in Mean RSBQ Subscale Scores at Week 24

    RSBQ is a caregiver-completed questionnaire that measures the frequency of current disease characteristics in individuals with Rett Syndrome. The 45-item RSBQ is comprised of 8 subscales: 1) general mood (score range 0-16), 2) breathing problems (range 0-10), 3) hand behaviors (range 0-12), 4) face movements (range 0-8), 5) body rocking (BR)/expressionless face (range 0-12), 6) night-time behaviors (range 0-6), 7) anxiety/fear (range 0-8), 8) walking/standing (range 0-4). Each item is rated on a 3-point scale (0-2); 0 indicating an item that is "not true as far as you know," 1 indicating an item is "somewhat or sometimes true," and 2 indicating an item that is "very true or often true." Item 31 ("Uses eye gaze to convey feelings, needs and wishes") is reverse scored (0 indicating "very true or often true", 1 indicating "somewhat or sometimes true," and 2 indicating "not true as far as you know"). Higher scores representing greater severity. CFB = Change from Baseline.

    Time frame: Baseline; Week 24

  5. Change From Baseline in Mean 9-items Motor Behavioral Assessment (MBA-9) Total Score and Subscale Scores at Week 24

    MBA-9 is derived from the full MBA scale (37 Rett syndrome symptoms) by selecting the items deemed amenable to change and which reflected areas of meaningful clinical change. the MBA-9 includes 9 items (1-Regression of motor skills; 2-Poor eye/social contact; 3-Lack of sustained interest; 4-Does not reach for objects or people; 5-Chewing difficulties; 6-Speech disturbance; 7-Hand clumsiness; 8-Dystonia and 9-Hypertonia/rigidity); for each item, the severity of current symptoms is rated by the investigator on a 5-point numerical scale ranging from 0 to 4 with higher scores representing greater severity (0 = normal or never; 1 = mild or rare; 2 = moderate or occasional; 3 = marked or frequent; 4 = very severe or constant). Total MBA-9 score was calculated by summing the scores of 9 different subscale items. The total summed score ranges from 0 to 36, with higher scores representing greater severity. CFB = Change from Baseline.

    Time frame: Baseline; Week 24

  6. Change From Baseline in Mean Children's Sleep Habits Questionnaire (CSHQ) Total Score and Subscale Scores at Week 24

    CSHQ is a caregiver-completed sleep screening instrument designed for school-aged children; which includes 33 items within 8 subscales: 1) bedtime resistance (score range 6-18), 2) sleep onset delay (range 1-3), 3) sleep duration (range 3-9), 4) sleep anxiety (range 4-12), 5) night wakings (range 3-9), 6) parasomnias (range 7-21), 7) sleep-disordered breathing (range 3-9), 8) daytime sleepiness (range 8-24). Item scores range from 1 to 3, where 3="usually" (≥5 times/week), 2="sometimes" (2-4 times/week), and 1="rarely" (≤1 time/week); for items 31 and 32; 3=fall asleep, 2=very sleepy, 1=not sleepy. In general, a score of 3 indicates greater severity, however, 6 items (1-Goes to bed at same time; 2-Falls asleep in 20 minutes; 3-Falls asleep in own bed; 10-Sleeps the right amount; 11-Sleeps same amount each day; 26-Wakes by himself) are reverse scored. Total summed score ranges from 33 to 99, with higher scores representing more disturbed sleep behavior. CFB = Change from Baseline.

    Time frame: Baseline; Week 24

07

Results

Posted Dec 29, 2021
Limitations and caveats
This study was terminated early due to enrollment challenges and the Coronavirus disease-2019 (COVID-19) pandemic. Numbers of participants in each treatment groups were small, which precluded the planned formal statistical inferences and limited data interpretation.

Participant flow

Participant flow — Overall Study
Milestone5 mg/kg/Day GWP42003-P15 mg/kg/Day GWP42003-PPlacebo
Started10910
Completed764
Not completed336
Withdrew: Withdrawal of consent due to covid-19001
Withdrew: Withdrawal by subject001
Withdrew: Withdrawal (covid-19)020
Withdrew: Physician decision213
Withdrew: Sponsor decision - covid-19 precaution001
Withdrew: Adverse event100

Outcome measures

PrimaryChange From Baseline in the Mean Rett Syndrome Behaviour Questionnaire (RSBQ) Total Score at Week 24 for the 15 mg/kg/Day GWP42003-P Dose Level Compared With Placebo

RSBQ is a caregiver-completed questionnaire that measures the frequency of current disease characteristics (45 items) in individuals with Rett Syndrome. Each item is rated on a 3-point scale (0-2); 0 indicating an item that is "not true as far as you know," 1 indicating an item is "somewhat or sometimes true," and 2 indicating an item that is "very true or often true." Item 31 ("Uses eye gaze to convey feelings, needs and wishes") is reverse scored (0 indicating "very true or often true", 1 indicating "somewhat or sometimes true," and 2 indicating "not true as far as you know"). The total summed score ranges from 0 to 90, with higher scores representing greater severity.

Time frame:
Baseline; Week 24
Reported as:
Mean · units on a scale
Change From Baseline in the Mean Rett Syndrome Behaviour Questionnaire (RSBQ) Total Score at Week 24 for the 15 mg/kg/Day GWP42003-P Dose Level Compared With Placebo
units on a scale15 mg/kg/Day GWP42003-PPlacebo
Baseline45.9 ± 16.7750.0 ± 7.56
Change from Baseline at Week 24-12.1 ± 13.63-6.1 ± 7.22
SecondaryChange From Baseline in the Mean RSBQ Total Score at Week 24 for the 5 mg/kg/Day GWP42003-P Dose Level Compared With Placebo

RSBQ is a caregiver-completed questionnaire that measures the frequency of current disease characteristics (45 items) in individuals with Rett Syndrome. Each item is rated on a 3-point scale (0-2); 0 indicating an item that is "not true as far as you know," 1 indicating an item is "somewhat or sometimes true," and 2 indicating an item that is "very true or often true." Item 31 ("Uses eye gaze to convey feelings, needs and wishes") is reverse scored (0 indicating "very true or often true", 1 indicating "somewhat or sometimes true," and 2 indicating "not true as far as you know"). The total summed score ranges from 0 to 90, with higher scores represent greater severity.

Time frame:
Baseline; Week 24
Reported as:
Mean · units on a scale
Change From Baseline in the Mean RSBQ Total Score at Week 24 for the 5 mg/kg/Day GWP42003-P Dose Level Compared With Placebo
units on a scale5 mg/kg/Day GWP42003-PPlacebo
Baseline39.8 ± 12.8050.0 ± 7.56
Change from Baseline at Week 240.4 ± 12.51-6.1 ± 7.22
SecondaryMean Clinical Global Impressions - Improvement (CGI-I) Score at Week 24

CGI-I is a 7-point scale that requires the clinician to assess how much a participant's illness has improved or worsened relative to a Baseline state at the beginning of the intervention. This is rated as: 1 = very much improved; 2 = much improved; 3 = minimally improved; 4 = no change; 5 = minimally worse; 6 = much worse; or 7 = very much worse.

Time frame:
Baseline; Week 24
Reported as:
Mean · units on a scale
Mean Clinical Global Impressions - Improvement (CGI-I) Score at Week 24
units on a scale5 mg/kg/Day GWP42003-P15 mg/kg/Day GWP42003-PPlacebo
Mean Clinical Global Impressions - Improvement (CGI-I) Score at Week 243.2 ± 1.202.9 ± 1.073.1 ± 0.38
SecondaryChange From Baseline in Mean Clinician Global Impressions - Severity (CGI-S) Score at Week 24

CGI-S is a 7-point scale that requires the clinician to rate the severity of the participant's illness at the time of assessment relative to the clinician's experience with participants who had the same diagnosis. This is rated as: 1 = normal, not at all ill; 2 = borderline ill; 3 = mildly ill; 4 = moderately ill; 5 = markedly ill; 6 = severely ill; or 7 = extremely ill.

Time frame:
Baseline; Week 24
Reported as:
Mean · units on a scale
Change From Baseline in Mean Clinician Global Impressions - Severity (CGI-S) Score at Week 24
units on a scale5 mg/kg/Day GWP42003-P15 mg/kg/Day GWP42003-PPlacebo
Baseline4.3 ± 1.254.2 ± 0.674.4 ± 0.84
Change from Baseline at Week 24-0.1 ± 0.33-0.1 ± 0.380.0 ± 0.00
SecondaryChange From Baseline in Mean RSBQ Subscale Scores at Week 24

RSBQ is a caregiver-completed questionnaire that measures the frequency of current disease characteristics in individuals with Rett Syndrome. The 45-item RSBQ is comprised of 8 subscales: 1) general mood (score range 0-16), 2) breathing problems (range 0-10), 3) hand behaviors (range 0-12), 4) face movements (range 0-8), 5) body rocking (BR)/expressionless face (range 0-12), 6) night-time behaviors (range 0-6), 7) anxiety/fear (range 0-8), 8) walking/standing (range 0-4). Each item is rated on a 3-point scale (0-2); 0 indicating an item that is "not true as far as you know," 1 indicating an item is "somewhat or sometimes true," and 2 indicating an item that is "very true or often true." Item 31 ("Uses eye gaze to convey feelings, needs and wishes") is reverse scored (0 indicating "very true or often true", 1 indicating "somewhat or sometimes true," and 2 indicating "not true as far as you know"). Higher scores representing greater severity. CFB = Change from Baseline.

Time frame:
Baseline; Week 24
Reported as:
Mean · units on a scale
Change From Baseline in Mean RSBQ Subscale Scores at Week 24
units on a scale5 mg/kg/Day GWP42003-P15 mg/kg/Day GWP42003-PPlacebo
Baseline General Mood Score6.0 ± 3.658.2 ± 4.588.9 ± 3.14
CFB General Mood Score-0.6 ± 2.70-4.9 ± 2.67-2.6 ± 2.57
Baseline Breathing Problems Score4.7 ± 2.455.0 ± 3.085.0 ± 3.43
CFB Breathing Problems Score0.2 ± 1.86-1.0 ± 1.53-0.3 ± 1.25
Baseline Hand Behaviors Score7.8 ± 2.157.6 ± 3.549.1 ± 2.08
CFB Hand Behaviors Score0.7 ± 2.24-0.9 ± 3.290.1 ± 0.90
Baseline Face Movements Score2.3 ± 2.454.6 ± 2.134.3 ± 2.21
CFB Face Movements Score0.0 ± 1.12-1.4 ± 1.72-0.1 ± 1.07
Baseline Body Rocking/Expressionless Face Score4.5 ± 2.595.1 ± 1.965.4 ± 2.59
CFB Body Rocking/Expressionless Face Score0.6 ± 2.46-0.6 ± 1.13-0.1 ± 1.86
Baseline Night-time Behaviors Score0.8 ± 1.140.8 ± 0.971.8 ± 1.69
CFB Night-time Behaviors Score0.2 ± 0.97-0.1 ± 1.46-0.3 ± 1.11
Baseline Anxiety/Fear Score4.0 ± 1.894.6 ± 2.465.1 ± 1.45
CFB Anxiety/Fear Score-0.2 ± 1.92-1.3 ± 2.29-1.7 ± 0.95
Baseline Walking/Standing Score2.7 ± 1.642.1 ± 1.362.9 ± 1.29
CFB Walking/Standing Score0.9 ± 2.090.0 ± 0.580.1 ± 1.07
SecondaryChange From Baseline in Mean 9-items Motor Behavioral Assessment (MBA-9) Total Score and Subscale Scores at Week 24

MBA-9 is derived from the full MBA scale (37 Rett syndrome symptoms) by selecting the items deemed amenable to change and which reflected areas of meaningful clinical change. the MBA-9 includes 9 items (1-Regression of motor skills; 2-Poor eye/social contact; 3-Lack of sustained interest; 4-Does not reach for objects or people; 5-Chewing difficulties; 6-Speech disturbance; 7-Hand clumsiness; 8-Dystonia and 9-Hypertonia/rigidity); for each item, the severity of current symptoms is rated by the investigator on a 5-point numerical scale ranging from 0 to 4 with higher scores representing greater severity (0 = normal or never; 1 = mild or rare; 2 = moderate or occasional; 3 = marked or frequent; 4 = very severe or constant). Total MBA-9 score was calculated by summing the scores of 9 different subscale items. The total summed score ranges from 0 to 36, with higher scores representing greater severity. CFB = Change from Baseline.

Time frame:
Baseline; Week 24
Reported as:
Mean · units on a scale
Change From Baseline in Mean 9-items Motor Behavioral Assessment (MBA-9) Total Score and Subscale Scores at Week 24
units on a scale5 mg/kg/Day GWP42003-P15 mg/kg/Day GWP42003-PPlacebo
Baseline Regression of Motor Skills2.2 ± 1.232.6 ± 0.882.6 ± 0.84
CFB Regression of Motor Skills0.3 ± 1.58-0.3 ± 0.490.0 ± 0.58
Baseline Poor Eye/Social Contact1.7 ± 0.821.6 ± 1.011.5 ± 0.97
CFB Poor Eye/Social Contact0.0 ± 0.87-0.1 ± 0.69-0.9 ± 1.07
Baseline Lack of Sustained Interest1.8 ± 0.792.1 ± 1.171.5 ± 0.71
CFB Lack of Sustained Interest0.0 ± 0.71-0.3 ± 1.11-0.1 ± 0.38
Baseline Does Not Reach for Objects or People2.0 ± 1.251.9 ± 1.052.3 ± 1.25
CFB Does Not Reach for Objects or People-0.4 ± 2.24-0.4 ± 0.980.1 ± 1.21
Baseline Chewing Difficulties1.3 ± 1.341.3 ± 0.501.1 ± 0.74
CFB Chewing Difficulties-0.2 ± 0.670.0 ± 0.000.4 ± 0.53
Baseline Speech Disturbance3.0 ± 0.472.8 ± 0.832.7 ± 0.48
CFB Speech Disturbance0.0 ± 0.000.0 ± 0.580.3 ± 0.49
Baseline Hand Clumsiness2.8 ± 1.142.8 ± 1.563.1 ± 1.10
CFB Hand Clumsiness-0.6 ± 1.33-0.4 ± 1.130.0 ± 0.58
Baseline Dysonia1.0 ± 1.411.2 ± 1.561.0 ± 1.41
CFB Dysonia0.4 ± 1.42-0.1 ± 0.900.1 ± 1.46
Baseline Hypertonia/Rigidity1.4 ± 1.511.1 ± 1.451.0 ± 1.41
CFB Hypertonia/Rigidity0.4 ± 0.73-0.1 ± 0.380.0 ± 1.00
Baseline MBA-9 Total Score17.2 ± 5.8117.3 ± 6.7816.8 ± 5.96
CFB MBA-9 Total Score0.0 ± 4.87-1.9 ± 4.060.0 ± 3.92
SecondaryChange From Baseline in Mean Children's Sleep Habits Questionnaire (CSHQ) Total Score and Subscale Scores at Week 24

CSHQ is a caregiver-completed sleep screening instrument designed for school-aged children; which includes 33 items within 8 subscales: 1) bedtime resistance (score range 6-18), 2) sleep onset delay (range 1-3), 3) sleep duration (range 3-9), 4) sleep anxiety (range 4-12), 5) night wakings (range 3-9), 6) parasomnias (range 7-21), 7) sleep-disordered breathing (range 3-9), 8) daytime sleepiness (range 8-24). Item scores range from 1 to 3, where 3="usually" (≥5 times/week), 2="sometimes" (2-4 times/week), and 1="rarely" (≤1 time/week); for items 31 and 32; 3=fall asleep, 2=very sleepy, 1=not sleepy. In general, a score of 3 indicates greater severity, however, 6 items (1-Goes to bed at same time; 2-Falls asleep in 20 minutes; 3-Falls asleep in own bed; 10-Sleeps the right amount; 11-Sleeps same amount each day; 26-Wakes by himself) are reverse scored. Total summed score ranges from 33 to 99, with higher scores representing more disturbed sleep behavior. CFB = Change from Baseline.

Time frame:
Baseline; Week 24
Reported as:
Mean · units on a scale
Change From Baseline in Mean Children's Sleep Habits Questionnaire (CSHQ) Total Score and Subscale Scores at Week 24
units on a scale5 mg/kg/Day GWP42003-P15 mg/kg/Day GWP42003-PPlacebo
Baseline Total Score49.8 ± 9.7546.7 ± 4.9049.4 ± 5.42
CFB Total score-1.6 ± 6.17-5.0 ± 6.14-3.7 ± 4.07
Baseline Bedtime resistance9.2 ± 3.437.3 ± 2.127.0 ± 1.25
CFB Bedtime resistance0.0 ± 1.00-0.4 ± 1.27-0.1 ± 1.68
Baseline Sleep onset delay1.5 ± 0.711.4 ± 0.531.8 ± 0.79
CFB Sleep onset delay0.1 ± 1.27-0.1 ± 0.69-0.6 ± 0.53
Baseline Sleep duration4.7 ± 2.413.4 ± 0.734.5 ± 1.58
CFB Sleep duration0.4 ± 1.13-0.3 ± 0.95-0.4 ± 1.72
Baseline Sleep anxiety5.6 ± 1.654.6 ± 0.734.9 ± 1.10
CFB Sleep anxiety-0.1 ± 0.78-0.1 ± 0.380.0 ± 1.15
Baseline Night wakings5.3 ± 2.364.4 ± 1.334.6 ± 1.43
CFB Night wakings-0.4 ± 0.88-0.6 ± 1.400.1 ± 0.69
Baseline Parasomnias11.0 ± 1.4910.4 ± 1.4211.7 ± 2.63
CFB Parasomnias-0.6 ± 1.51-1.1 ± 1.68-1.4 ± 2.30
Baseline Sleep disordered breathing4.2 ± 1.694.0 ± 1.223.7 ± 1.06
CFB Sleep disordered breathing-0.4 ± 1.74-0.9 ± 1.07-0.1 ± 0.38
Baseline Daytime sleepiness11.6 ± 3.2013.2 ± 2.3913.7 ± 2.50
CFB Daytime sleepiness-0.7 ± 3.64-1.4 ± 2.07-1.3 ± 2.56

Adverse events

Collected over Up to approximately 207 days. Non-serious events are listed at a 1% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
5 mg/kg/Day GWP42003-P0/11 (0%)2/11 (18.2%)9/11 (81.8%)
15 mg/kg/Day GWP42003-P0/9 (0%)2/9 (22.2%)7/9 (77.8%)
Placebo0/9 (0%)1/9 (11.1%)7/9 (77.8%)
Most frequent serious events
Most frequent serious events
Event5 mg/kg/Day GWP42003-P15 mg/kg/Day GWP42003-PPlacebo
COVID-19Infections and infestations1/111/91/9
Alanine aminotransferase increasedInvestigations0/111/90/9
Aspartate aminotransferase increasedInvestigations0/111/90/9
DyskinesiaNervous system disorders0/111/90/9
Lower respiratory tract infectionInfections and infestations1/110/90/9
Most frequent other events
Showing 10 of 58
Most frequent other events
Event5 mg/kg/Day GWP42003-P15 mg/kg/Day GWP42003-PPlacebo
Upper respiratory tract infectionInfections and infestations1/110/93/9
LethargyNervous system disorders0/113/90/9
DiarrhoeaGastrointestinal disorders2/112/90/9
VomitingGastrointestinal disorders0/112/90/9
PyrexiaGeneral disorders0/112/91/9
Decreased appetiteMetabolism and nutrition disorders0/112/90/9
InsomniaPsychiatric disorders1/110/92/9
NasopharyngitisInfections and infestations2/110/91/9
EosinophiliaBlood and lymphatic system disorders0/110/91/9
MacrocytosisBlood and lymphatic system disorders1/110/91/9

Baseline characteristics

One participant assigned to the 5 mg/kg/Day placebo group was misdosed with 5 mg/kg/Day GWP42003-P. The participant was included in the 5 mg/kg/Day placebo group in the Intent-to-Treat Set but was included in the 5 mg/kg/day GWP42003-P group in the Safety Analysis Set (for which Baseline data are reported).

Age, Categorical
Age, Categorical(Participants)5 mg/kg/Day GWP42003-P15 mg/kg/Day GWP42003-PPlaceboTotal
<=18 years119929
Between 18 and 65 years0000
>=65 years0000
Age, Continuous
Age, Continuous(years)5 mg/kg/Day GWP42003-P15 mg/kg/Day GWP42003-PPlaceboTotal
Mean9.7 ± 6.0210.7 ± 3.648.6 ± 5.539.7 ± 5.11
Sex: Female, Male
Sex: Female, Male(Participants)5 mg/kg/Day GWP42003-P15 mg/kg/Day GWP42003-PPlaceboTotal
Female119929
Male0000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)5 mg/kg/Day GWP42003-P15 mg/kg/Day GWP42003-PPlaceboTotal
American Indian or Alaska Native1001
Asian0000
Native Hawaiian or Other Pacific Islander0000
Black or African American0000
White109928
More than one race0000
Unknown or Not Reported0000
08

Study locations

26 sites
  • Clinical Trial Site
    Birmingham, Alabama 35294-0021, United States
  • Clinical Trial Site
    San Diego, California 92123, United States
  • Clinical Trial Site
    Aurora, Colorado 80045, United States
  • Clinical Trial Site
    Chicago, Illinois 60612, United States
  • Clinical Trial Site
    Baltimore, Maryland 21205, United States
  • Clinical Trial Site
    Boston, Massachusetts 02115, United States
  • Clinical Trial Site
    Saint Paul, Minnesota 55101, United States
  • Clinical Trial Site
    Saint Louis, Missouri 63110-1093, United States
  • Clinical Trial Site
    Bronx, New York 10467, United States
  • Clinical Trial Site
    Cincinnati, Ohio 45229, United States
  • Clinical Trial Site
    Philadelphia, Pennsylvania 19104, United States
  • Clinical Trial Site
    Greenwood, South Carolina 29646, United States
  • Clinical Trial Site
    Nashville, Tennessee 37232, United States
  • Clinical Trial Site
    Houston, Texas 77030, United States
  • Clinical Trial Site
    Genoa, 16147, Italy
  • Clinical Trial Site
    Messina, 98124, Italy
  • Clinical Trial Site
    Milan, 20142, Italy
  • Clinical Trial Site
    Rome, 00165, Italy
  • Clinical Trial Site
    Barcelona, 08022, Spain
  • Clinical Trial Site
    Barcelona, 08950, Spain
  • Clinical Trial Site
    Madrid, 28009, Spain
  • Clinical Trial Site
    Madrid, 28040, Spain
  • Clinical Trial Site
    Valencia, 46026, Spain
  • Clinical Trial Site
    Liverpool, L12 2AP, United Kingdom
  • Clinical Trial Site
    London, SE1 7EU, United Kingdom
  • Clinical Trial Site
    London, SE5 8BB, United Kingdom
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2019 to primary completion in Jan 2021, 17 months.

Results were first posted in Dec 2021, 11 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 19, 2019
First posted
Feb 21, 2019
StartActual
Jul 29, 2019
Primary completionActual
Jan 21, 2021
CompletionActual
Jan 21, 2021
Results first posted
Dec 29, 2021
Last update
Sep 2, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 2, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03848832
Responsible party
Sponsor
First posted
Feb 21, 2019
Start date
Jul 29, 2019
Primary completion
Jan 21, 2021
Completion
Jan 21, 2021
Results posted
Dec 29, 2021
Last update
Sep 2, 2022

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Aug 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cannabidiol

Start the discussion